Search research articles
Contact Us
Filters
Showing results (141-150 of 165) with videos related to
Page
of 17
Sort By:
Molecular Cancer Therapeutics
|
July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
Andrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Allergy
|
December 14, 2024
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study
Sayantani B Sindher, Kari C Nadeau, R Sharon Chinthrajah, et al.
Ebiomedicine
|
September 13, 2024
Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19
Bei Wang, Jacquelynn Golubov, Erin M Oswald, et al.
Cancer Research
|
November 29, 2013
Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis
Joanne R Doherty, Chunying Yang, Kristen E N Scott, et al.
BMJ Open
|
October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study
Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Nature Communications
|
June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
Dean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19
Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 3, 2026
Local and circulating cytotoxic CD4⁺ T cells are early markers of disease activity in pediatric Crohn's disease
Veronika Niederlova, Kyle Kimler, Hengqi Betty Zheng, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
Allergy
|
December 14, 2024
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
R Sharon Chinthrajah, Sayantani B Sindher, Kari C Nadeau, et al.
Page
of 17
Search research articles
Search
Showing results (141-150 of 165) with videos related to
Sort By:
Page
of 17
Molecular Cancer Therapeutics
|
July 6, 2022
Anti-Extra Domain B Splice Variant of Fibronectin Antibody-Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade
Andrea T Hooper, Kimberly Marquette, Chao-Pei Betty Chang, et al.
Allergy
|
December 14, 2024
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study
Sayantani B Sindher, Kari C Nadeau, R Sharon Chinthrajah, et al.
Ebiomedicine
|
September 13, 2024
Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19
Bei Wang, Jacquelynn Golubov, Erin M Oswald, et al.
Cancer Research
|
November 29, 2013
Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis
Joanne R Doherty, Chunying Yang, Kristen E N Scott, et al.
BMJ Open
|
October 9, 2024
Assessing the safety and pharmacokinetics of casirivimab and imdevimab (CAS+IMD) in a cohort of pregnant outpatients with COVID-19: results from an adaptive, multicentre, randomised, double-blind, phase 1/2/3 study
Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Nature Communications
|
June 17, 2023
Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration
Dean Follmann, Meagan P O'Brien, Jonathan Fintzi, et al.
Journal of the Pediatric Infectious Diseases Society
|
October 1, 2024
Safety and Pharmacokinetics of Casirivimab and Imdevimab (CAS + IMD) in Pediatric Outpatients With COVID-19
Thomas D Norton, Mazhar Thakur, Samit Ganguly, et al.
Medrxiv : the Preprint Server for Health Sciences
|
July 3, 2026
Local and circulating cytotoxic CD4⁺ T cells are early markers of disease activity in pediatric Crohn's disease
Veronika Niederlova, Kyle Kimler, Hengqi Betty Zheng, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases
|
July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19
Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
Allergy
|
December 14, 2024
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
R Sharon Chinthrajah, Sayantani B Sindher, Kari C Nadeau, et al.
Page
of 17